Henan Lingrui Pharmaceutical Co., Ltd.

XSSC:600285 Stock Report

Market Cap: CN¥12.7b

Henan Lingrui Pharmaceutical Past Earnings Performance

Past criteria checks 6/6

Henan Lingrui Pharmaceutical has been growing earnings at an average annual rate of 18.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 11.4% per year. Henan Lingrui Pharmaceutical's return on equity is 23.3%, and it has net margins of 19%.

Key information

18.4%

Earnings growth rate

18.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate11.4%
Return on equity23.3%
Net Margin19.0%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Henan Lingrui Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600285 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,5646761,755118
30 Jun 243,5176641,742114
31 Mar 243,4326141,717109
31 Dec 233,3115681,680110
30 Sep 233,2325261,667123
30 Jun 233,2005121,678126
31 Mar 233,1084791,651126
31 Dec 223,0024651,610125
30 Sep 222,9174401,58192
30 Jun 222,8414121,56489
31 Mar 222,7863961,52395
31 Dec 212,6943621,48586
30 Sep 212,6353831,475110
30 Jun 212,5133681,411102
31 Mar 212,4303461,398100
31 Dec 202,3323251,34298
30 Sep 202,2153021,26094
30 Jun 202,1632881,23288
31 Mar 202,0682701,17878
31 Dec 192,1572941,22379
30 Sep 192,1492921,22563
30 Jun 192,1182801,21265
31 Mar 192,0782701,20157
31 Dec 182,0532431,17258
30 Sep 182,1392401,25550
30 Jun 182,1202301,20075
31 Mar 181,9902231,09967
31 Dec 171,8492171,01456
30 Sep 171,69719888235
30 Jun 171,6083818600
31 Mar 171,5133648110
31 Dec 161,4393467670
30 Sep 161,3153656720
30 Jun 161,2251526140
31 Mar 161,1331415620
31 Dec 151,0851325190
30 Sep 151,0061194810
30 Jun 159361154420
31 Mar 15901974390
31 Dec 14826764100
30 Sep 14802753960
30 Jun 14757653650
31 Mar 14718593360
31 Dec 136871053180

Quality Earnings: 600285 has high quality earnings.

Growing Profit Margin: 600285's current net profit margins (19%) are higher than last year (16.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600285's earnings have grown by 18.4% per year over the past 5 years.

Accelerating Growth: 600285's earnings growth over the past year (28.4%) exceeds its 5-year average (18.4% per year).

Earnings vs Industry: 600285 earnings growth over the past year (28.4%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 600285's Return on Equity (23.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 21:04
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Henan Lingrui Pharmaceutical Co., Ltd. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Bo ChenChasing Securities
Yang LuoCLSA